Immune activation of the monocyte-derived dendritic cells using patients own circulating tumor cells.
Circulating tumor cells
Dendritic cells
Immunotherapy
MetaCell
Personalized medicine
T cells
Journal
Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
20
10
2021
accepted:
09
03
2022
pubmed:
27
4
2022
medline:
26
10
2022
entrez:
26
4
2022
Statut:
ppublish
Résumé
Dendritic cell (DC) therapy counts to the promising strategies how to weaken and eradicate cancer disease. We aimed to develop a good manufacturing practice (GMP) protocol for monocyte-derived DC (Mo-DC) maturation using circulating tumor cells lysates with subsequent experimental T-cell priming in vitro. DC differentiation was induced from a population of immunomagnetically enriched CD14 + monocytes out of the leukapheresis samples (n = 6). The separation was provided automatically, in a closed bag system, using CliniMACS Prodigy New protocols for mMo-DC production using automatization and CTC lysates were introduced including a feasible in vitro assay for mMo-DC efficacy evaluation. Gene expression analysis revealed elevation for following genes in NTBC (T cells) subset primed by mMo-DCs: CD8A, CD4, MKI67, MIF, TNFA, CD86, and CD80 (p ≤ 0.01). Summarizing the presented data, we might conclude mMo-DCs were generated using CliniMACS Prodigy® machine and CTC lysates in a homogenous manner showing a potential to generate NTBC activation in co-cultures. Identification of the activation signals in T-cell population by simple multimarker-qPCRs could fasten the process of effective mMo-DC production.
Sections du résumé
BACKGROUND
BACKGROUND
Dendritic cell (DC) therapy counts to the promising strategies how to weaken and eradicate cancer disease. We aimed to develop a good manufacturing practice (GMP) protocol for monocyte-derived DC (Mo-DC) maturation using circulating tumor cells lysates with subsequent experimental T-cell priming in vitro.
METHODS
METHODS
DC differentiation was induced from a population of immunomagnetically enriched CD14 + monocytes out of the leukapheresis samples (n = 6). The separation was provided automatically, in a closed bag system, using CliniMACS Prodigy
RESULTS
RESULTS
New protocols for mMo-DC production using automatization and CTC lysates were introduced including a feasible in vitro assay for mMo-DC efficacy evaluation. Gene expression analysis revealed elevation for following genes in NTBC (T cells) subset primed by mMo-DCs: CD8A, CD4, MKI67, MIF, TNFA, CD86, and CD80 (p ≤ 0.01).
CONCLUSION
CONCLUSIONS
Summarizing the presented data, we might conclude mMo-DCs were generated using CliniMACS Prodigy® machine and CTC lysates in a homogenous manner showing a potential to generate NTBC activation in co-cultures. Identification of the activation signals in T-cell population by simple multimarker-qPCRs could fasten the process of effective mMo-DC production.
Identifiants
pubmed: 35471603
doi: 10.1007/s00262-022-03189-2
pii: 10.1007/s00262-022-03189-2
doi:
Substances chimiques
Granulocyte-Macrophage Colony-Stimulating Factor
83869-56-1
Interleukin-4
207137-56-2
Interleukin-6
0
Prostaglandins E
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2901-2911Subventions
Organisme : KZ
ID : IGA-KZ-2017-1-16
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Collin M, Bigley V (2018) Human dendritic cell subsets: an update. Immunology 154(1):3–20. https://doi.org/10.1111/imm.12888
doi: 10.1111/imm.12888
pubmed: 29313948
pmcid: 5904714
Cancel J-C, Crozat K, Dalod M, Mattiuz R (2019) Are conventional type 1 dendritic cells critical for protective antitumor Immunity and How? Front Immunol 10(19):9–9. https://doi.org/10.1038/s41467-019-13368-y (ISSN 1664-3224)
doi: 10.1038/s41467-019-13368-y
pubmed: 30809220
pmcid: 6379659
Eisenbarth SC (2019) Dendritic cell subsets in T cell programming: location dictates function. Nat Rev Immunol 19(2):89–103. https://doi.org/10.1038/s41577-018-0088-1.ISSN1474-1733
doi: 10.1038/s41577-018-0088-1.ISSN1474-1733
pubmed: 30464294
pmcid: 7755085
Cintolo JA, Datta J, Mathew SJ, Czerniecki BJ (2012) Dendritic cell-based vaccines: barriers and opportunities. Future Oncol 8(10):1273–1299. https://doi.org/10.2217/fon.12.125 (ISSN 1479-6694)
doi: 10.2217/fon.12.125
pubmed: 23130928
Yu J, Sun H, Cao W, Song Y, Jiang Z (2022) Research progress on dendritic cell vaccines in cancer immunotherapy. Exp Hematol Oncol 11(1):3. https://doi.org/10.1186/s40164-022-00257-2
doi: 10.1186/s40164-022-00257-2
pubmed: 35074008
pmcid: 8784280
PantelSpeicher KMR (2016) The biology of circulating tumor cells. Oncogene 35(10):1216–1224. https://doi.org/10.1038/onc.2015.192.ISSN0950-9232
doi: 10.1038/onc.2015.192.ISSN0950-9232
Kolostova K, Zhang Y, Hoffman RM, Bobek V (2014) In vitro culture and characterization of human lung cancer circulating tumor cells isolated by size exclusion from an orthotopic nude-mouse model expressing fluorescent protein. J Fluorescence 24(5):1531–1536. https://doi.org/10.1007/s10895-014-1439-3 (ISSN 1053-0509)
doi: 10.1007/s10895-014-1439-3
Kolostova K, Matkowski R, Jędryka M et al (2015) The added value of circulating tumor cells examination in ovarian cancer staging. Am J Cancer Res 5(11):3363–3375
pubmed: 26807317
pmcid: 4697683
Nath SC, Harper L, Rancourt DE (2020) Cell-based therapy manufacturing in stirred suspension bioreactor: thoughts for cGMP compliance. Front Bioeng Biotechnol 8(8):1–16. https://doi.org/10.3389/fbioe.2020.599674 (ISSN 2296-4185)
doi: 10.3389/fbioe.2020.599674
Hopewell EL, Cox C (2020) Manufacturing dendritic cells for immunotherapy: monocyte enrichment. Mol Ther Methods Clin Dev 16(1):155–160. https://doi.org/10.1016/j.omtm.2019.12.017 (ISSN 23290501)
doi: 10.1016/j.omtm.2019.12.017
pubmed: 32055643
pmcid: 7005329
Perez CR, De Palma M (2019) Engineering dendritic cell vaccines to improve cancer immunotherapy. Nat Commun 10(1):1–10. https://doi.org/10.1038/s41467-019-13368-y (ISSN 2041-1723)
doi: 10.1038/s41467-019-13368-y
Silvestris N, Ciliberto G, De Paoli P, Apolone G, Lavitrano ML, Pierotti MA, Stanta G (2017) Liquid dynamic medicine and N-of-1 clinical trials a change of perspective in oncology research. J Exp Clin Cancer Res 36(1):5. https://doi.org/10.1186/s13046-017-0598-x (ISSN 1756-9966)
doi: 10.1186/s13046-017-0598-x
Pantel K, Alix-Panabières C (2019) Liquid biopsy and minimal residual disease—latest advances and implications for cure. Nat Rev Clin Oncol 16(7):409–424. https://doi.org/10.1038/s41571-019-0187-3 (ISSN 1759-4774)
doi: 10.1038/s41571-019-0187-3
pubmed: 30796368
Heiser A, Coleman D, Dannull J et al (2002) Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Investig 109(3):409–417. https://doi.org/10.1172/JCI14364 (ISSN 0021-9738)
doi: 10.1172/JCI14364
pubmed: 11828001
pmcid: 150859
Saxena M, Balan S, Roudko V, Bhardwaj N (2018) Towards superior dendritic-cell vaccines for cancer therapy. Nat Biomed Eng 2(6):341–346. https://doi.org/10.1038/s41551-018-0250-x (ISSN 2157-846X)
doi: 10.1038/s41551-018-0250-x
pubmed: 30116654
pmcid: 6089533
Koido S, Kashiwaba M, Chen D, Gendler S, Kufe D, Gong J (2000) Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. J Immunol 165(10):5713–5719. https://doi.org/10.4049/jimmunol.165.10.5713 (ISSN 0022-1767)
doi: 10.4049/jimmunol.165.10.5713
pubmed: 11067929
Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D (2020) Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol 20(1):7–24. https://doi.org/10.1038/s41577-019-0210-z (ISSN 1474-1733)
doi: 10.1038/s41577-019-0210-z
pubmed: 31467405
Constantino J, Gomes C, Falcão A, Cruz MT, Neves BM (2016) Antitumor dendritic cell–based vaccines: lessons from 20 years of clinical trials and future perspectives. Transl Res 168:74–95. https://doi.org/10.1016/j.trsl.2015.07.008 (ISSN 19315244)
doi: 10.1016/j.trsl.2015.07.008
pubmed: 26297944
Amberger DC, Schmetzer HM (2020) Dendritic cells of leukemic origin: specialized antigen-presenting cells as potential treatment tools for patients with Myeloid Leukemia. Transfus Med Hemother 47(6):432–443. https://doi.org/10.1159/000512452 (ISSN 1660-3796)
doi: 10.1159/000512452
pubmed: 33442338
pmcid: 7768130
Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N (2000) Consequences of Cell Death. J Exp Med 191(3):423–434. https://doi.org/10.1084/jem.191.3.423 (ISSN 0022-1007)
doi: 10.1084/jem.191.3.423
pubmed: 10662788
pmcid: 2195816
Podrazil M, Horvath R, Becht E et al (2015) Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. Oncotarget 6(20):18192–18205. https://doi.org/10.18632/oncotarget.4145 (ISSN 1949-2553)
doi: 10.18632/oncotarget.4145
pubmed: 26078335
pmcid: 4627245
Oh SA, Wu DC, Cheung J (2020) PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer. Nat Cancer 1(1):681–691. https://doi.org/10.1038/s43018-020-0075-x
doi: 10.1038/s43018-020-0075-x
pubmed: 35122038
Morita M, Gravel S-P, Hulea L, Larsson O, Pollak M, St-Pierre J, Topisirovic I (2015) MTOR coordinates protein synthesis, mitochondrial activity and proliferation. Cell Cycle 14(4):473–480. https://doi.org/10.4161/15384101.2014.991572 (ISSN 1538-4101)
doi: 10.4161/15384101.2014.991572
pubmed: 25590164
pmcid: 4615141
Szatmari I, Töröcsik D, Agostini M, Nagy T, Gurnell M, Barta E, Chatterjee K, Nagy L (2007) PPARγ regulates the function of human dendritic cells primarily by altering lipid metabolism. Blood 110(9):3271–3280. https://doi.org/10.1182/blood-2007-06-096222 (ISSN 0006-4971)
doi: 10.1182/blood-2007-06-096222
pubmed: 17664351
Pearce EJ, Everts B (2015) Dendritic cell metabolism. Nat Rev Immunol 15(1):18–29. https://doi.org/10.1038/nri3771 (ISSN 1474-1733)
doi: 10.1038/nri3771
pubmed: 25534620
pmcid: 4495583
Krawczyk CM, Holowka T, Sun J et al (2010) Toll-like receptor–induced changes in glycolytic metabolism regulate dendritic cell activation. Blood 115(23):4742–4749. https://doi.org/10.1182/blood-2009-10-249540 (ISSN 0006-4971)
doi: 10.1182/blood-2009-10-249540
pubmed: 20351312
pmcid: 2890190